Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial.

[1]  H. Putter,et al.  Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Putter,et al.  Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial , 2019, The Lancet. Oncology.

[3]  L. Colvin.  Chemotherapy-induced peripheral neuropathy: where are we now? , 2019, Pain.

[4]  Jae-Weon Kim,et al.  Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  U. Hänninen,et al.  Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy , 2019, Acta oncologica.

[6]  P. Fayers,et al.  General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. , 2019, European journal of cancer.

[7]  A. Olshen,et al.  Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors. , 2018, Journal of pain and symptom management.

[8]  M. C. Vos,et al.  Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study. , 2018, Gynecologic oncology.

[9]  H. Putter,et al.  Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial , 2018, The Lancet. Oncology.

[10]  E. Basch,et al.  The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice , 2017, Quality of Life Research.

[11]  M. Stockler,et al.  Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial , 2016, British Journal of Cancer.

[12]  H. Putter,et al.  Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[13]  J. Ledermann,et al.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[14]  M. Dolan,et al.  Chemotherapy-induced peripheral neuropathy: Current status and progress. , 2016, Gynecologic oncology.

[15]  H. Putter,et al.  Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. , 2015, International Journal of Radiation Oncology, Biology, Physics.

[16]  M. Ewertz,et al.  Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. , 2015, European journal of cancer.

[17]  Gaetano Rocco,et al.  Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. H. van den Berg,et al.  Incidence of polyneuropathy in Utrecht, the Netherlands , 2015, Neurology.

[19]  M. C. Vos,et al.  Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. , 2014, Gynecologic oncology.

[20]  H. Putter,et al.  Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. , 2012, European journal of cancer.

[21]  Lonneke V van de Poll-Franse,et al.  Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Taphoorn,et al.  Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. , 2011, European journal of cancer.

[23]  P. Fayers,et al.  Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Dariusz Wydra,et al.  The European Organization for Research and Treatment of Cancer (EORTC) Quality‐of‐Life questionnaire cervical cancer module , 2006, Cancer.

[25]  A. Bottomley,et al.  An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. , 2003, European journal of cancer.

[26]  A. Cull,et al.  Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. , 2001, European journal of cancer.

[27]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Andrew Bottomley,et al.  EORTC QLQ-C30 Scoring Manual , 1995 .